cenicriviroc (TBR-652) / Dong-A, AbbVie, Takeda  >>  Phase 2
Welcome,         Profile    Billing    Logout  

14 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cenicriviroc (TBR-652) / Takeda, AbbVie
NCT01338883: Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus

Completed
2b
143
US
Cenicriviroc 100 mg, Cenicriviroc 200 mg + Truvada, Sustiva + Truvada
Tobira Therapeutics, Inc.
HIV-1 Infection
12/12
06/13
NCT01474954: Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors

Terminated
2b
5
US
University of California, San Francisco, Tobira Therapeutics, Inc.
HIV Infection
12/12
12/12
NCT02128828: Effect of Cenicriviroc on HIV Neurocognitive Impairment

Completed
2
20
US
cenicriviroc, TBR-652
University of Hawaii, Tobira Therapeutics, Inc.
AIDS Dementia Complex, HIV-1-Associated Cognitive Motor Complex, Human Immunodeficiency Virus
06/16
06/16
CENTAUR, NCT02217475 / 2014-003164-21: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

Checkmark Year 2 analysis of CENTAUR study at EASL 2018 [screenshot]
Apr 2018 - Apr 2018: Year 2 analysis of CENTAUR study at EASL 2018 [screenshot]
Checkmark CENTAUR trial in NASH
Sep 2017 - Sep 2017: CENTAUR trial in NASH
Completed
2
289
US, Europe, RoW
Cenicriviroc, TBR-652, Placebo
Tobira Therapeutics, Inc.
Nonalcoholic Steatohepatitis
06/16
06/17
ORION, NCT02330549: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD

Completed
2
45
US
Cenicriviroc 150 mg, Placebo
Tobira Therapeutics, Inc.
Prediabetic State, Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
08/16
09/16
2015-002955-85: A phase II feasibility study to assess changes in patients who have been identified as having cognitive function impairment following the addition of a new drug to an existing effective regime of three HIV antiretrovirals drugs

Terminated
2
10
Europe
Cenicriviroc, TBR-652, Tablet
Imperial College London, Imperial College Healthcare NHS Trust Biomedical Research Centre
Human Immunodeficiency Virus, HIV, Diseases [C] - Virus Diseases [C02]
 
 
PERSEUS, NCT02653625: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis

Completed
2
24
Canada, US
Cenicriviroc 150 mg, CVC 150 mg
Tobira Therapeutics, Inc.
Primary Sclerosing Cholangitis
08/17
08/17
TANDEM, NCT03517540 / 2017-004208-24: Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

Checkmark Initiation of P2b TANDEM trial for NASH
Oct 2018 - Oct 2018: Initiation of P2b TANDEM trial for NASH
Completed
2
193
Europe, Canada, US, RoW
Tropifexor (LJN452), LJN452, Cenicriviroc (CVC), CVC
Novartis Pharmaceuticals, Allergan
Non-alcoholic Steatohepatitis (NASH)
09/20
10/20
Rollover, NCT03059446 / 2016-004754-15: Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

Terminated
2
167
Europe, US, RoW
Cenicriviroc, CVC
Tobira Therapeutics, Inc.
Nonalcoholic Steatohepatitis, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease
01/21
01/21
NCT04500418 / 2020-001493-29: Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients

Terminated
2
45
Europe
Cenicriviroc (CVC), Cenicriviroc Mesylate, Placebo
Charite University, Berlin, Germany, Allergan
Covid19
07/21
07/21
I-SPY_COVID, NCT04488081: I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Recruiting
2
1500
US
Remdesivir, GS-5734, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Firazyr, Apremilast, Otezla, dornase alfa, Pulmozyme, Celecoxib, celebrex, Famotidine, Pepcid, IC14, Aviptadil, Zyesami, narsoplimab, OMS721, Cyproheptadine, periactin, Cyclosporine, CsA
QuantumLeap Healthcare Collaborative, University of California, San Francisco, University of Pennsylvania, Emory University, University of Alabama at Birmingham, University of Colorado, Denver, University of Southern California, Yale University, Wake Forest University Health Sciences, Sanford Health, Long Beach Memorial Medical Center, Georgetown University, University of California, Davis, Hoag Memorial Hospital Presbyterian, Main Line Health, DHR Health Institute for Research and Development, University of California, Irvine, Corewell Health, Kaiser Permanente, University of Michigan, West Virginia University, University of Miami, University Hospitals Cleveland Medical Center, Virtua Health, M.D. Anderson Cancer Center
COVID-19
07/28
07/30
NCT04334915: Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Withdrawn
2
0
NA
Cenicriviroc Mesylate (CVC), Placebo
National Institute of Allergy and Infectious Diseases (NIAID), Allergan
HIV Infections
08/24
08/24
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Completed
2
110
US
CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg
National Institute of Allergy and Infectious Diseases (NIAID), AbbVie
HIV-1-infection, Elevated Cardiovascular Risk
06/24
06/24
NCT01092104: A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

Completed
1/2
52
US
TBR-652, TBR-652 Matching Placebo, TBR-652 50 mg, TBR-652 75 mg, TBR-652 100 mg, TBR-652 150 mg
Tobira Therapeutics, Inc.
HIV-1 Infection
11/09
11/09

Download Options